ClinicalTrials.Veeva

Menu

Rocuronium vs Cis-atracurium: Do Rocuronium Still 'ROCKS' In Coronary Artery Bypass Grafting

I

Institut Jantung Negara

Status

Completed

Conditions

Coronary Artery Disease
Postoperative Pulmonary Atelectasis
Postoperative Pulmonary Complication
Hypothermic Cardiopulmonary Bypass
Coronary Artery Bypass Grafting
Neuromuscular Blockade

Treatments

Drug: Nimbex 10 MG in 5 ML Injection
Drug: Rocuronium Bromide 10 MG/ML

Study type

Observational

Funder types

Other

Identifiers

NCT06102915
IJNREC/631/2023

Details and patient eligibility

About

The current trend in most cardiac surgeries was to use rocuronium as it provides faster recovery in train-of-four ratio compared to other aminosteroid non-depolarising neuromuscular blocker. However, as most cardiac centres' standard of care does not perform any neuromuscular monitoring nor antagonism of neuromuscular blockade effect, residual neuromuscular blockade could potentially be the key to delayed extubation. As such, Cis-atracurium's organ-independent Hofmann elimination could be in favour.

Enrollment

289 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients that undergo general anaesthesia for CABG surgery requiring neuromuscular blockade of either rocuronium or cis-atracurium

Exclusion criteria

  1. Recent history of pulmonary infection four weeks before surgery
  2. Exposed to both neuromuscular blockade within 24 hours perioperatively
  3. Patients intubated or on tracheostomies pre-operatively
  4. Any missing or incomplete data

Trial design

289 participants in 2 patient groups

Rocuronium
Description:
Rocuronium 1mg/kg to be given at induction of anaesthesia and another 1mg/kg would be given when the patient is on hypothermic cardiopulmonary bypass
Treatment:
Drug: Rocuronium Bromide 10 MG/ML
Cis-atracurium
Description:
Cis-atracurium 0.2mg/kg to be given at induction of anaesthesia and another 0.2mg/kg would be given when the patient is on hypothermic cardiopulmonary bypass
Treatment:
Drug: Nimbex 10 MG in 5 ML Injection

Trial contacts and locations

1

Loading...

Central trial contact

SONG LIN LOW, MBBS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems